Shijiazhuang Pharmaceutical Group Co., Ltd., by the Hebei Pharmaceutical Group Corporation, Shijiazhuang Pharmaceutical Group Corporation and three other companies first on August 21, 1997 formed from the combination, is the pharmaceutical industry's first combination approach to the formation of large pharmaceutical companies, but also in Hebei Province is one major pillar of enterprise groups.

Shijiazhuang Pharmaceutical Group total assets of 11.5 billion, employs approximately 20,000 people, Run with the pharmaceutical, life-medicine, medicine in the Connaught, Europa medicine, NBP medicine, pharmaceutical and other mail transfer more than ten subsidiary companies, located in Hebei, Shanxi, Tianjin, Jilin, Liaoning and Inner Mongolia. One subsidiary based in Hong Kong - China Pharmaceutical Group Co., Ltd. is the first overseas listed Chinese pharmaceutical industry company, is listed in Hong Kong one of the largest pharmaceutical, but also Hong Kong's Hang Seng Index constituent stocks of red chips, continuous twice by the world famous "Forbes" magazine as the world turnover in Asia below $ 1,000,000,000 100 best listed companies. July 2009, China's pharmaceutical list, "the first listed company of China's most competitive pharmaceutical Top 20" list.

Shijiazhuang Pharmaceutical Group is a science, industry and trade in one of the large system drug companies, mainly engaged in pharmaceutical product development, production and sales. Products include antibiotics, vitamins, cardiovascular, anti-inflammatory, digestive and respiratory system drugs such as medication six series of nearly a thousand varieties, penicillin and vitamin series is the leading series of products. Currently, the annual production capacity of vitamin C reached 3.5 million tons, penicillin series of API production capacity reached 1.6 million tons ,7-ACA production scale will reach 1,600 tons/year, the annual production capacity of amoxicillin 6,000 tons of caffeine annual production capacity of 8,000 tons, ranking first in the world. Shijiazhuang Pharmaceutical Group's annual production capacity of finished products for the powder 3 billion, 20 billion tablets, capsules, 8000000000, 1000000000 capsule. Shijiazhuang Pharmaceutical Group of leading product output, size, strength are among the best in the country, and has developed into the largest "chemical raw materials production base" and "comprehensive preparation production base" one. Shijiazhuang Pharmaceutical Group currently has 30 varieties of products sold over one billion, product sales all over the country and the world more than sixty countries and regions.

Shijiazhuang Pharmaceutical Group was established ten years, continuous innovation, forge ahead, to obtain by leaps and bounds, obtained encouraging results, has won the national medical system, advanced group, the quality and efficiency of advanced enterprises, commitment to product quality assured units, the National Labor Award, China's environmental protection enterprises Love Award Honor. In 2009, the Shijiazhuang Pharmaceutical Group to realize an annual sales income of 10.6 billion non-tax, pre-tax profits, profits were 14.6 billion and 12.1 billion yuan, 500,000,000 yuan turned over to various types of taxes. The whole group for direct exports 450 million U.S. dollars, the highest in the forefront of China's pharmaceutical manufacturing business.

in research and development, the Shijiazhuang Pharmaceutical Group relying on the company's "post-doctoral research station ", state-level enterprise technology centers," 863 Program "High-tech industrial base, and Engineering Center of Hebei Province agents in recent years has developed a number of national drug ninety involving biotechnology, chiral synthetic drugs, liposomes , transdermal preparations, molecular microcapsule agent multiple areas. CSPC is currently more than 220 pieces of patent applications were filed, there are 116 authorized to apply for PCT international patent 17. Among them, countries with independent intellectual property rights of a class of drugs, "NBP" is a global leader in the field of stroke treatment drugs in China with independent intellectual property rights of third countries, a class of drugs, to fill the gaps in a class of drugs in Hebei Province State history and 86 countries around the world protected by patents. Currently, the company has with the United States and South Korea, two well-known companies, signed a soft capsule NBP market in Europe, America and South Korea the right to use the patent transfer agreement, the Chinese pharmaceutical companies to create the world's most developed countries to transfer drugs to the intellectual property of precedent for country and the nation won the honor. In 2008, under the leadership of the Ministry of Science, the lead organization set up a Chinese antibiotic Industrial Technology Innovation Alliance and the State Science and Technology Support Programme project support. In the country "a major new drug" science and technology reporting in major projects, an incubator of innovative drugs, three innovative drug research and development of technology platforms and six new drug development project located in stone medicine, access to policy projects within the industry to support the largest enterprises.

in product quality, the Shijiazhuang Pharmaceutical Group to establish a comprehensive three-level quality management system, all drugs have passed the GMP certification, all affiliated enterprises have passed ISO9000, OHSAS18000 and ISO14001 certification, product market remain seized of 100%pass rate. At the same time, enhance the quality of enterprise content technology, there are caffeine, vitamin C, VB12, amoxicillin and other products made 8 API EU COS certification, access to high-end European and American pharmaceutical market into a "pass."

in brand building, CSPC has "SPG", "Europa "two" China Famous Trademark; by the global assessment of brand value, one of five World Brand Laboratory Evaluation, "Stone medicine" brand four times in a row since 2005, appeared in the "500 most valuable Chinese brands"; Shijiazhuang Pharmaceutical Group three consecutive among the top 500 Chinese enterprises and China's most short-listed brand value in 2008 Enterprise Award, the 2008 chemical raw material medicine manufacturing industry in China pioneer enterprises.

Looking ahead, stone medicine will continue to uphold "good medicine, for the Chinese" corporate philosophy, commitment to the cause of human health, with more, newer and better drugs contributing to society, for the construction of the Shijiazhuang Pharmaceutical Group to become first-class, large-scale modernization of the Global 500 pharmaceutical companies and work hard.